| Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy |
Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies. The financial picture remains strong, bolstered further by a partnership with AstraZeneca. Promised data readouts in late 2025 represent important potential catalysts. |
seekingalpha.com |
2025-05-15 14:58:09 |
Czytaj oryginał (ang.) |
| Cellectis Reports Financial Results for the First Quarter 2025 |
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the first quarter 2025, ending March 31, 2025, and provided a business update. |
globenewswire.com |
2025-05-12 20:30:00 |
Czytaj oryginał (ang.) |
| Cellectis to Report First Quarter Financial Results on May 12, 2025 |
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. |
globenewswire.com |
2025-05-06 20:30:00 |
Czytaj oryginał (ang.) |
| Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting |
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 13-17, 2025 in New Orleans. |
globenewswire.com |
2025-04-28 20:30:00 |
Czytaj oryginał (ang.) |
| Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal |
Cellectis S.A. NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology. |
marketbeat.com |
2025-04-22 13:00:17 |
Czytaj oryginał (ang.) |
| Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript |
Cellectis S.A. (NASDAQ:CLLS ) Q4 2024 Earnings Conference Call March 14, 2025 8:00 AM ET Company Participants Arthur Stril - CFO and Chief Business Officer Andre Choulika - CEO Adrian Kilcoyne - CMO Conference Call Participants Gena Wang - Barclays Jack Allen - Baird Sebastiaan van der Schoot - Kempen Silvan Tuerkcan - Citizens Jack Allen - Baird Hangfei Fu - Jefferies Operator Good day, everyone, and welcome to today's Cellectis Full Year 2024 Earnings Conference Call. |
seekingalpha.com |
2025-03-14 12:36:24 |
Czytaj oryginał (ang.) |
| Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update |
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL. |
globenewswire.com |
2025-03-13 20:07:00 |
Czytaj oryginał (ang.) |
| Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 |
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market. |
globenewswire.com |
2025-03-07 18:30:00 |
Czytaj oryginał (ang.) |
| Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 |
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcases an innovative strategy for T cell engineering that leverages the pro-inflammatory properties of interleukin 2 (IL-2) with the objective to enhance CAR T cell efficacy against solid tumors, at the American Association for Cancer Research – Immuno-oncology (AACR-IO), taking place on February 23-26, 2025 in Los Angeles, CA. |
globenewswire.com |
2025-02-24 03:30:00 |
Czytaj oryginał (ang.) |
| Cellectis: Poised To Start Answering Questions In 2025 |
Cellectis S.A.'s pipeline updates highlight promising advancements in engineered, allogeneic cell therapies. The financial overview indicates a strong cash position, but ongoing R&D expenses pose a risk to its longevity. Key data updates are coming in 2025 that will give us a look at their lead program in a larger population. |
seekingalpha.com |
2024-12-12 17:08:31 |
Czytaj oryginał (ang.) |
| Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) |
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the final tranche of €5 million (“Tranche C”) under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the “EIB) on December 28, 2022 (the "Finance Contract"). With the drawdown of Tranche C, the Company has drawn down the full €40 million available under the Finance Contract. Tranche C is expected to be disbursed by the EIB by December 18, 2024. The Company plans to use the proceeds of Tranche C towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22 and UCART20x22. |
globenewswire.com |
2024-12-10 18:30:00 |
Czytaj oryginał (ang.) |
| Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting |
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data to enhance CAR T cell activity against solid tumors while preventing potential toxicity, will be presented at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC), that will take place on November 6-10, 2024 in Houston, Texas. |
globenewswire.com |
2024-11-05 18:30:00 |
Czytaj oryginał (ang.) |
| Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript |
Cellectis S.A. (NASDAQ:CLLS ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Arthur Stril - Interim Chief Financial Officer Andre Choulika - Chief Executive Officer Adrian Kilcoyne - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Jack Allen - Baird Ashiq Mubarack - Citi Kuan-Hung Lin - Wells Fargo Luisa Morgado - Van Lanschot Kempen Silvan Tuerkcan - Citizens JMP Operator Good morning, everyone, and welcome to the Cellectis Third Quarter 2024 Earnings Call. |
seekingalpha.com |
2024-11-05 15:59:57 |
Czytaj oryginał (ang.) |
| Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 |
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the nine-month period ending September 30, 2024. |
globenewswire.com |
2024-11-04 18:30:00 |
Czytaj oryginał (ang.) |
| Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 |
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market. |
globenewswire.com |
2024-10-30 18:30:00 |
Czytaj oryginał (ang.) |
| Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress |
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that they will be showcasing pre-clinical data that permit the design of an efficient and specific TALE base editors (TALEB) as well as a process to enhance the efficacy of non-viral gene insertion in hematopoietic stem and progenitor cells (HSPCs) at the European Society of Cell and Gene Therapy 31st annual congress, that will take place on October 22-25, 2024, in Roma, Italy. |
globenewswire.com |
2024-10-22 06:00:00 |
Czytaj oryginał (ang.) |
| Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety |
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a scientific article in Science Advances suggesting that TALEN®-edited MUC1 CAR T-cells could be a potential treatment option for advance-stage triple negative breast cancer (TNBC) patients with limited therapeutic options. |
globenewswire.com |
2024-09-03 20:30:00 |
Czytaj oryginał (ang.) |
| Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors |
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Molecular Therapy demonstrating TALEN®-mediated gene editing capabilities for design of SMART DUAL CAR T-cells, which efficiently target immunotherapy recalcitrant solid tumors while mitigating potential safety risks. |
globenewswire.com |
2024-08-26 20:30:00 |
Czytaj oryginał (ang.) |
| Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer |
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. |
globenewswire.com |
2024-08-07 06:00:00 |
Czytaj oryginał (ang.) |
| Cellectis Provides Financial Results for the Second Quarter 2024 |
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024. |
globenewswire.com |
2024-08-06 20:30:00 |
Czytaj oryginał (ang.) |
| FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment |
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Cellectis' CLLS52 (alemtuzumab), an Investigational Medicinal Product (IMP) used as part of the lymphodepletion regimen associated with UCART22, evaluated in the BALLI-01 clinical trial in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). |
globenewswire.com |
2024-08-01 20:30:00 |
Czytaj oryginał (ang.) |
| FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment |
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug (ODD) and Rare Pediatric Disease Designation (RPDD) Status to UCART22 product candidate for the treatment of Acute Lymphoblastic Leukemia (ALL). |
globenewswire.com |
2024-07-25 20:30:00 |
Czytaj oryginał (ang.) |
| Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS) |
Cellectis (CLLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-07-10 14:37:27 |
Czytaj oryginał (ang.) |
| Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 |
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. |
globenewswire.com |
2024-06-28 20:30:00 |
Czytaj oryginał (ang.) |
| Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing |
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing. |
globenewswire.com |
2024-06-20 20:30:00 |
Czytaj oryginał (ang.) |
| Cellectis (CLLS) Upgraded to Buy: Here's Why |
Cellectis (CLLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-06-18 17:01:20 |
Czytaj oryginał (ang.) |
| After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS) |
The heavy selling pressure might have exhausted for Cellectis (CLLS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-06-18 14:35:23 |
Czytaj oryginał (ang.) |
| Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications |
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease. |
globenewswire.com |
2024-06-12 20:30:00 |
Czytaj oryginał (ang.) |
| Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia |
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the European Commission (EC) has granted an Orphan Drug Designation (ODD) to its product candidate UCART22, for the treatment of Acute Lymphoblastic Leukemia (ALL). |
globenewswire.com |
2024-06-04 20:30:00 |
Czytaj oryginał (ang.) |